Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups

ConclusionsCost-effective provision of teplizumab to target individuals depends on the price of teplizumab and genetic and antibody characteristics of treated individuals. As the drug makes its way to the  market, findings from this study will help inform policymakers and payers on cost-effective ways to provide this innovative but expensive drug to at-risk individuals.
Source: PharmacoEconomics - Category: Health Management Source Type: research